Table of Contents
International Scholarly Research Notices
Volume 2014 (2014), Article ID 810128, 4 pages
Research Article

Application of Hydrotropic Solubilization in Spectrophotometric Estimation of Lornoxicam from Tablets

1Department of Pharmaceutics, M.S. Ramaiah College of Pharmacy, MSRIT Post, MSR Nagar, Bangalore 560054, India
2Department of Pharmacognosy, M.S. Ramaiah College of Pharmacy, MSRIT Post, MSR Nagar, Bangalore 560054, India

Received 25 April 2014; Revised 4 September 2014; Accepted 5 September 2014; Published 29 October 2014

Academic Editor: Romána Zelkó

Copyright © 2014 Sindhu Abraham et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Lornoxicam is a selective cyclooxygenase-1 and cyclooxygenase-2 inhibitor that exhibits anti-inflammatory, analgesic, and antipyretic activities. It is used in osteoarthritis and rheumatoid arthritis; and in treatment of postoperative pain and primary dysmenorrhoea. Lornoxicam is completely insoluble in water but soluble in alkaline solutions. Hydrotropic solubilization is a technique used to increase the aqueous solubility of poorly water-soluble drugs and the present study was aimed at developing a hydrotropic technique to increase the solubility of lornoxicam, using 2 M sodium benzoate as the hydrotropic agent. Beer’s law was obeyed in the concentration range of 4–24 μg/mL at 381 nm. The solubility of lornoxicam in distilled water considerably increased with the addition of a hydrotropic agent. The analysis of tablets indicated good correlation between the amounts estimated and label claim. The LOD and LOQ of lornoxicam were found to be 0.34 μg/mL and 1.038 μg/mL, respectively, indicating good sensitivity of the proposed method. The percentage recovery was found to be 99.99%–100.21%. Thus the proposed method is new, simple, environmentally friendly, accurate, and cost effective and can be successfully employed in routine analysis of lornoxicam in tablets.